Skip to main content

Verkazia FDA Approval History

Last updated by Judith Stewart, BPharm on July 13, 2021.

FDA Approved: Yes (First approved June 23, 2021)
Brand name: Verkazia
Generic name: cyclosporine
Dosage form: Ophthalmic Emulsion
Company: Santen Inc.
Treatment for: Vernal Keratoconjunctivitis

Verkazia (cyclosporine) is a calcineurin inhibitor immunosuppressant indicated for the treatment of vernal keratoconjunctivitis (VKC) in children and adults.

  • Verkazia works by inhibiting T-cell activation and reducing the level of immune cells and mediators that cause the chronic, severe, and potentially debilitating allergic inflammation of the ocular surface associated with vernal keratoconjunctivitis.
  • Verkazia is administered by instilling one drop in each affected eye four times daily.
  • Common adverse reactions include eye pain and eye pruritus.

Development timeline for Verkazia

DateArticle
Jun 24, 2021Approval FDA Approves Verkazia (cyclosporine ophthalmic emulsion) for the Treatment of Vernal Keratoconjunctivitis

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.